Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase <scp>III</scp> high‐risk B acute lymphoblastic leukemia trial <scp>AALL</scp>0232Amanda M. DiNofia, Richard Aplenc, Alix E. Seif et al.|Cancer Medicine|2017Cited by 14
Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic LeukemiaGrace E. Lee, Richard Aplenc, Rochelle Bagatell et al.|Journal of the Pediatric Infectious Diseases Society|2014Cited by 8
Resource Utilization and Cost Analysis By Treatment Arm on the Children’s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children’s Oncology GroupAmanda M. DiNofia, Richard Aplenc, Eric Larsen et al.|Blood|2014Cited by 0